| Chemical Name: | N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide |
| Molecular Weight: | 462.56 |
| Formula: | C27H31FN4O2 |
| Purity: | ≥98% |
| CAS#: | 1355326-35-0 |
| Solubility: | DMSO up to 100 mM |
| Storage: | Powder:4oC 1 year DMSO:4oC3 month-20oC 1 year |
AGI-5198 (IDH-C35) is the first highly potent and selective mutant IDH1 inhibitor that was shown to have anti-tumor efficacy and lower tumor 2‑HG (2-hydroxyglutarate) in vivo. It inhibits IDH1 R132H mutant and R132C mutant in vitro with IC50 ~0.07 µM and ~0.16 µM, respectively, but not wild-type IDH1 or any of the examined IDH2 isoforms (IC50 > 100 μM). AGI-5198 has good cellular activities in TS603 glioma cell line, also inhibits 2-HG production in HT1080 and U87MG cells with IC50 ~0.48 µM and IC50 ~0.07 µM, respectively. In R132H-IDH1 glioma xenografts (TS603), AGI-5198 (450 mg/kg) caused 50-60% growth inhibition with no signs of toxicity during three weeks of daily treatment, but it did not affect the growth of IDH1 wild-type glioma xenografts (TS516). Under conditions of near complete R-2HG (R-2-hydroxyglutarate) inhibition, AGI-5198 induced demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation. Blockade of mutant IDH1 impaired the growth of IDH1-mutant—but not IDH1-wild-type—glioma cells without appreciable changes in genome-wide DNA methylation. AGI-5198 could serve as a very useful chemical probe to assess the biological consequences of IDH1 mutations and the potential of IDH1 inhibitor for treating IDH1 mutant tumors.
How to Use:
In vitro: AGI-5198 was suggested to be used at 1.5-10µM final concentration in vitro.
In vivo: AGI-5198 could be orally dosed to mice at 150-450 mg/kg once per day for up to 3 weeks in glioma xenografts. It could be intraperitoneally (IP) dosed to mice at 50-150 mg/kg once or twice per day (formulation: 0.5% MC and 0.2% Tween 80) in the other animal studies.
Reference:
- 1. Dan Rohle, et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. (2013) Science.340(6132):626-30.
- 2. Janeta Popovici-Muller, et al. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. (2012) ACS Med. Chem. Lett. 3 (10), pp 850–855
- 3. Lenny Dang, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. (2009) Nature 462, 739-744.
- 4. Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. (2012) Nature. 483(7390):479-83.
- 5. Popovicimuller Janeta, et al. THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE. (2012) PCT WO 2012009678.
AGI-5198_spec.pdf
AGI-5198_MSDS.pdfProducts are for research use only. Not for human use.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
我做的是细胞因子的刺激和抑制某条通路后观察是否有影响，分组为空白组，空白+抑制剂，刺激组，刺激+抑制剂，最开始用的单因素方差分析，LSD-T和SNK-Q检验，但是同学说我这里面有两个处理因素，所以不能单因素方差分析，应该直接空白和空白+抑制，空白和刺激，刺激和刺激+抑制剂进行独立样本T检验，现在脑子是混乱的，拜托园子里的大神们帮我看看，感激不尽！！
天然产物，大多都有颜色，
存在干扰，多数情况下需要做样品的阴性对照，
尽量能用荧光的方法，
之前我们做过，将两个试剂盒的方法合并后，做的，
效果还可以
支原体培养则是取样后在培养基上培养，看有多少支原体菌落会长出，是比较直观和可信的结果。
总体来讲，这两种检查手段可信度都较高，结合一起，不仅可以可靠的知道有无解脲支原体感染，还能知道感染是否严重。
该试剂盒是一种时间分辨的荧光共振能量转移免疫分析，该反应是一个竞争免疫反应，即铕标的cAMP示踪复合物与体系中的cAMP竞争结合标有Alexa Fluor 647染料的cAMP抗体。铕标cAMP示踪复合物是通过Biotin标记的cAMP与铕标的抗生物素蛋白链菌素（streptavidin）与抗体的复合物紧密结合产生的。
当抗体结合到示踪剂上时，340nm的激发光激发铕标分子，导致能量转移到Alexa Fluor 647染料上，结果产生665nm的发射光。荧光的强度与样品中的cAMP含量成反比。
本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体，激动剂刺激导致665nm的荧光强度降低，而拮抗剂则可以逆转这一效应；对于偶联Gαi的受体，在激动剂刺激的同时用forskolin刺激cAMP产生，那么激动剂则抑制forskolin诱导的cAMP的生成，因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。
该试剂盒的灵敏度很高，室温下反应在20h内是稳定的。本试剂盒适用于在384孔板中进行24μl的微量分析。
1. 姜黄素是一个典型的HAT抑制剂。
2. 针对P300: 在大约10年前，Cole和他的同事设计出了一种p300/CBP抑制剂，发表在nature杂志上。
希望能帮到你，望采纳！
